Study on the relationship between<sup>11</sup>C-PIB-PET/CT and neuropsychological scales in mild cognitive impairment and Alzheimer's disease

Wenhong Chen; Songtao Li; Yangyang Ma; Qing Zhao

doi:10.13406/j.cnki.cyxb.002928

您当前的位置：

首页 >

文章列表页 >

Study on the relationship between¹¹C-PIB-PET/CT and neuropsychological scales in mild cognitive impairment and Alzheimer's disease

Correlation analysis of cognitive impairment and central biomarkers | 更新时间：2022-06-24

- Study on the relationship between¹¹C-PIB-PET/CT and neuropsychological scales in mild cognitive impairment and Alzheimer's disease
- Journal of Shanxi Agricultural Sciences Vol. 46, Issue 11, Pages: 1370-1375(2021)
- 作者机构：
  
  吉林大学中日联谊医院南湖神经内科、吉林省记忆与认知障碍疾病工程实验室，长春　130000
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.002928
  CLC： R749.1
- Published：28 November 2021，
  
  Received：11 August 2021，
扫描看全文
Wenhong Chen, Songtao Li, Yangyang Ma, et al. Study on the relationship between¹¹C-PIB-PET/CT and neuropsychological scales in mild cognitive impairment and Alzheimer's disease. [J]. Journal of Shanxi Agricultural Sciences 46(11):1370-1375(2021)
DOI：

Wenhong Chen, Songtao Li, Yangyang Ma, et al. Study on the relationship between¹¹C-PIB-PET/CT and neuropsychological scales in mild cognitive impairment and Alzheimer's disease. [J]. Journal of Shanxi Agricultural Sciences 46(11):1370-1375(2021) DOI： 10.13406/j.cnki.cyxb.002928.

摘要

目的：

探索

C-匹兹堡化合物B正电子发射断层扫描成像（[N-methyl-

C]-2-（4-methylaminophenyl）-6-hydroxybenzothiazole，positron emission tomography，

C-PIB-PET/CT）与神经心理量表在轻度认知功能障碍（mild cognitive impairment，MCI）和阿尔茨海默病（Alzheimer's disease，AD）的关系。

方法：

选取吉林大学中日联谊医院神经内科2018年1月至2020年12月符合纳入标准的阿尔茨海默病及轻度认知功能障碍门诊及住院患者27例，收集患者一般资料、神经心理测试量表评分和

C-PIB-PET/CT成像，使用pMOD软件对患者

C-PIB-PET/CT成像进行处理，得到患者各脑区

C-PIB的标准摄取值比（standardized uptake value ratio，SUVR），组间对比得到显著差异的脑区，对所有患者具有显著差异的脑区SUVR与神经心理测试量表进行统计学分析。

结果：

①AD组SUVR均值高于MCI组SUVR均值，组间差异具有统计学意义（

0.01）。②2组患者SUVR值具有统计学差异（

0.01）的脑区为：左侧额下回（

=0.009）、左侧额上回（

=0.008）、左侧海马旁回及周围回（

=0.005）、右侧海马旁回及周围回（

=0.002）、左侧梭形回（

=0.002）、右侧梭形回（

=0.003）、左侧中央后回（

=0.003）、右侧楔叶（

=0.008）、左侧壳核（

=0.007）、右侧壳核（

=0.003）、右侧苍白球（

=0.006）、右侧扣带回前部（

=0.004）。③进一步将所有患者差异显著的脑区SUVR值与简易智能测试量表评分（mini-mental state examination，MMSE）及蒙特利尔认知评估（Montreal cognitive assessment，MoCA）行Pearson相关性分析。其中，左侧额上回（

=-0.454，

=0.029）、左侧海马旁回及周围回（

=-0.439，

=0.036）、左侧梭形回（

=-0.421，

=0.045）、左侧中央后回（

=-0.482，

=0.020）SUVR值与MMSE评分呈负相关（

0.05）。左侧额上回（

=-0.430，

=0.040）、左侧海马旁回及周围回（

=-0.418，

=0.047）、左侧梭形回（

=-0.454，

=0.030）、左侧中央后回（

=-0.477，

=0.021）、左侧壳核（

=-0.422，

=0.045）、右侧壳核（

=-0.419，

=0.047）SUVR值与MoCA评分呈负相关（

0.05）。

结论：

①AD组患者脑内

C-PIB的SUVR值显著高于MCI组患者。②AD组与MCI组患者多个脑区SUVR值具有显著差异。③额上回（左）、海马旁回及周围回（左）、梭形回（左）、中央后回（左）、壳核（左、右）部位Aβ蛋白沉积水平与认知功能损害相关。研究结果可为AD的早期识别诊断提供一定的影像学证据。

Abstract

Objective

To explore the relationship between [N-methyl-

C] -2- (4-methylaminophenyl) -6-hydroxybenzothiazole

positron emission tomography (

C-PIB-PET/CT) and neuropsychological scales in mild cognitive impairment (MCI) and Alzheimer's disease (AD).

Methods

Twenty-seven outpatients and inpatients with AD and MCI who met the inclusion criteria were selected from the Department of Neurology

China-Japan Union Hospital of Jilin University from January 2018 to December 2020

and general information

neuropsychological test scale scale scores and

C-PIB-PET/CT imaging of them were collected. The standardized uptake value ratio (SUVR) of

C-PIB in each brain region of the patients was obtained by processing the patient's

C-PIB-PET/CT imaging using pMOD software. The brain areas with significant differences were compared between the two groups

and the SUVR and neuropsychological test scale of all patients with statistical differences were statistically analyzed.

Results:

①The mean value of SUVR in the AD group was higher than the mean value of SUVR in the MCI group

and the differences between groups were statistically significant (

0.01). ②There were significant differences in the SUVR values of the brain regions of the two groups of paatients (

0.01): the left inferior frontal gyrus (

=0.009)

left superior frontal gyrus (

=0.008)

left parahippocampal gyrus and perirhinal gyrus (

=0.005)

right parahippocampal gyrus and perirhinal gyrus (

=0.002)

left syrinx (

=0.002)

right syrinx (

=0.003)

left postcentral gyrus (

=0.003)

right cuneus (

=0.008)

left cisternal nucleus (

=0.007)

right cisternal nucleus (

=0.003)

right pallidum (

=0.006) and right anterior cingulate gyrus (

=0.004). ③Further Pearson correlation analysis was performed between the significantly different SUVR values of brain regions and the scores of MMSE (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) scales in all patients. Among them

the SUVR values of the left superior frontal gyrus (

=-0.454

=0.029)

left parahippocampal gyrus and peripheral gyrus (

=-0.439

=0.036)

left syrinx (

=-0.421

=0.045)

and left postcentral gyrus (

=-0.482

=0.020) were negatively correlated with MMSE scores (

0.05). The left superior frontal gyrus (

=-0.430

=0.040)

left parahippocampal gyrus and peripheral gyrus (

=-0.418

=0.047)

left cingulate gyrus (

=-0.454

=0.030)

left postcentral gyrus (

=-0.477

=0.021)

left cisternal nucleus (

=-0.422

=0.045) and right cisternal nucleus (

=-0.419

=0.047) SUVR values were negatively correlated with MoCA scores (

0.05).

Conclusion:

①SUVR values of

CPIB in the brain of patients in the AD group were significantly higher than those of patients in the MCI group. ②SUVR values in several brain regions were significantly different between patients in the AD and MCI groups. ③The levels of Aβ protein deposition in the superior frontal gyrus (left)

parahippocampal gyrus and perirhinal gyrus (left)

sphenoid gyrus (left)

postcentral gyrus (left)

and nucleus accumbens (left and right) are associated with MCI. These results can provide some imaging evidence for the early identification and diagnosis of AD.

关键词

阿尔茨海默病轻度认知功能障碍11C-匹兹堡化合物B正电子发射断层扫描成像神经心理测试量表

Keywords

Alzheimer's diseasemild cognitive impairment[N-methyl-11C] -2- (4-methylaminophenyl) -6-hydroxybenzothiazole positron emission tomographyneuropsychological test

references

Bain LJ, Jedrziewski K, Morrison-Bogorad M, et al. Healthy brain aging: a meeting report from the Sylvan M. Cohen Annual Retreat of the University of Pennsylvania Institute on Aging[J]. Alzheimers Dement, 2008, 4(6):443-446.

Hane FT, Robinson M, Lee BY, et al. Recent progress in Alzheimer's disease research, part 3: diagnosis and treatment[J]. J Alzheimers Dis, 2017, 57(3):645-665.

Arendt T. Synaptic degeneration in Alzheimer's disease[J]. Acta Neuropathol, 2009, 118(1):167-179.

Carreiras MC, Mendes E, Perry MJ, et al. The multifactorial nature of Alzheimer's disease for developing potential therapeutics[J]. Curr Top Med Chem, 2013, 13(15):1745-1770.

李小玲, 杨泽. 阿尔茨海默病致病机制及相关遗传易感基因[J]. 中国老年保健医学, 2019, 17(3):90-92.

Dong Y, Li XH, Cheng JB, et al. Drug development for Alzheimer's disease: microglia induced neuroinflammation as a target?[J]. Int J Mol Sci, 2019, 20(3):558.

Hojjati SH, Ebrahimzadeh A, Khazaee A, et al. Predicting conversion from MCI to AD by integrating rs-fMRI and structural MRI[J]. Comput Biol Med, 2018, 102:30-39.

梁兵, 袁芳. 国际新近阿尔茨海默病痴呆诊断标准解读[J]. 重庆医科大学学报, 2017, 42(6):682-683.

Espinosa A, Alegret M, Pesini P, et al. Cognitive composites domain scores related to neuroimaging biomarkers within probableamnestic mild cognitive impairment-storage subtype[J]. J Alzheimers Dis, 2017, 57(2):447-459.

Cohen AD, Klunk WE. Early detection of Alzheimer's disease using PiB and FDG PET[J]. Neurobiol Dis, 2014, 72(Pt A):117-122.

Rowe CC, Villemagne VL. Brain amyloid imaging[J]. J Nucl Med, 2013, 41(1):11-18.

张美美, 张玉梅. 阿尔茨海默病生物标志物研究进展[J]. 中国医刊, 2021, 56(1):8-12.

Petersen RC. Mild cognitive impairment as a diagnostic entity[J]. J Intern Med, 2004, 256(3):183-194.

Gauthier S, Patterson C, Gordon M, et al. Commentary on “Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.” A Canadian perspective[J]. Alzheimer's Dement, 2011, 7(3):330-332.

Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer's disease[J]. Neurologia, 2000, 15(3):93-101.

Diniz BS, Nunes PV, Yassuda MS, et al. Mild cognitive impairment: cognitive screening or neuropsychological assessment?[J]. Braz J Psychiatry, 2008, 30(4):316-321.

Zhang S, Smailagic N, Hyde C, et al. 11C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment(MCI)[J]. Cochrane Database Syst Rev, 2014(7):CD010386.

Oddo S, Billings L, Kesslak JP, et al. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome[J]. Neuron, 2004, 43(3):321-332.

李阳, 李小凤. 4种神经心理学量表在阿尔茨海默病早期诊断中的应用比较研究[J]. 重庆医科大学学报, 2014, 39(4):488-492.

McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease[J]. Alzheimers Dement, 2011, 7(3):263-269.

Lim MYL, Loo JHY. Screening an elderly hearing impaired population for mild cognitive impairment using mini-mental state examination(MMSE)and Montreal cognitive assessment(MoCA)[J]. Int J Geriatr Psychiatry, 2018, 33(7):972-979.

Herholz K. PET studies in dementia[J]. Ann Nucl Med, 2003, 17(2):79-89.

Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study[J]. Neurology, 2011, 76(12):1085-1090.

He W, Liu DH, Radua J, et al. Meta-analytic comparison between PIB-PET and FDG-PET results in Alzheimer's disease and MCI[J]. Cell Biochem Biophys, 2015, 71(1):17-26.

Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B[J]. Ann Neurol, 2004, 55(3):306-319.

Jiménez-Bonilla JF, Quirce R, De Arcocha-Torres M, et al. A 5-year longitudinal evaluation in patients with mild cognitive impairment by11C-PIB PET/CT: a visual analysis[J]. Nucl Med Commun, 2019, 40(5):525-531.

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease[EB/OL]. [2021-03-08]. https://pubmed.ncbi.nlm.nih.gov/19339253/https://pubmed.ncbi.nlm.nih.gov/19339253/.

肖慧, 吴应行, 倪萍, 等. 阿尔茨海默病不同频段低频振幅静息态功能磁共振成像研究[J]. 中国医疗设备, 2014, 29(11):5-10.

Burgess N, Maguire EA, O'Keefe J. The human Hippocampus and spatial and episodic memory[J]. Neuron, 2002, 35(4):625-641.

Roh JH, Qiu AQ, Seo SW, et al. Volume reduction in subcortical regions according to severity of Alzheimer's disease[J]. J Neurol, 2011, 258(6):1013-1020.

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Role of neurofilament light chain protein in the early diagnosis of Alzheimer's disease

Screening blood genetic biomarkers of patients with mild cognitive impairment based on weighted gene co-expression network analysis and support vector machine modeling

Research advances of ferroptosis in Alzheimer's disease

Diagnosis of Alzheimer's disease based on whole-brain radiomics

Advances in the study of hippocampal subregion in Alzheimer's disease

Related Author

Xinling Meng

Maierhaba· Sailimu

Chenchen Guo

Qingyu Zhang

Feilan Chen

Qihao Guo

Wei Li

Yixin Chen

Related Institution

Department of Neurology, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University

Department of Geriatrics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital

School of Integrative Medicine,Tianjin University of Traditional Chinese Medicine

Office of Academic Research,Tianjin Sino-German University of Applied Sciences

Department of Radiology, The Second Affiliated Hospital of Chongqing Medical University

⁰

Study on the relationship between11C-PIB-PET/CT and neuropsychological scales in mild cognitive impairment and Alzheimer's disease

DOI：10.13406/j.cnki.cyxb.002928

摘要

Abstract

关键词

Keywords

references

Study on the relationship between¹¹C-PIB-PET/CT and neuropsychological scales in mild cognitive impairment and Alzheimer's disease